Abstract: Toll-like receptor 4 (TLR4) contributes to the pathogenesis of coronary ischemia/reperfusion (IR). To test whether the new TLR4 antagonist, ApTOLL, may prevent coronary IR damage, we administered 0.078 mg/kg ApTOLL or Placebo in pigs subjected to IR, analyzing the levels of cardiac troponins, matrix metalloproteinases, pro-, and anti-inflammatory cytokines, heart function, and tissue integrity over a period of 7 days after IR. Our results show that ApTOLL reduced cardiac troponin-1 24 h after administration, improving heart function, as detected by a significant recovery of the left ventricle ejection fraction (LVEF) and the shortening fraction (FS) cardiac parameters. The extension of necrotic and fibrotic areas was also reduced, as detected by Evans blue/2,3,5-triphenyltetrazolium chloride (TTC) staining, Hematoxylin/Eosine, and Masson Trichrome staining of heart sections, together with a significant reduction in the expression of the extracellular matrix-degrading, matrix metalloproteinase 9. Finally, the expression of the following cytokines, CCL1, CCL2, MIP1-A-B, CCL5, CD40L, C5/CSA, CXCL1, CXCL10, CXCL11, CXCL12, G-CSF, GM-CSF, ICAM-1, INF-g, IL1-a, IL1-b, IL-1Ra, IL2, IL4, IL5, IL6, IL8, IL10, IL12, IL13, IL16, IL17-A, IL17-E, IL18, IL21, IL27, IL32, MIF, SERPIN-E1, TNF-a, and TREM-1, were also assayed, detecting a pronounced decrease of pro-inflammatory cytokines after 7 days of treatment with ApTOLL. Altogether, our results show that ApTOLL is a promising new tool for the treatment of acute myocardial infarction (AMI).

Keywords: toll-like receptor 4; ApTOLL; acute myocardial infarction; cytokines; matrix metalloproteinases

1. Introduction

Acute myocardial infarction (AMI) is a major cause of morbidity and mortality worldwide [1]. Following coronary occlusion, ischemia leads to cardiac cell death [2], and, depending on the necrotic extension, an adverse remodeling can worsen recovery, leading to chronic heart failure (CHF), and hence impair the patient’s outcome [2].

Cardiac remodeling is a key step that will determine the severity of heart failure. It all starts in response to an injury sensed by an inflammatory response, which, in the case of AMI, is mediated by infiltration and activation of several cell types at the foci of inflammation, with the ultimate goal...
of removing dead cells and tissue repair. The process ends with the inflammation resolution phase, in which resolutive immune cells and fibroblasts promote cell proliferation, angiogenesis, and a replenishment of dead tissue with a collagen-based scar [3,4].

Among the different sensors of inflammation, toll-like receptors (TLRs) represent a key molecular link between innate and adaptive responses, mediating tissue injury and inflammation. Toll-like receptor 4 (TLR4) is a transmembrane signaling protein, which is the major pattern recognition receptor expressed by several cell types. Besides bacterial lipopolysaccharide, TLR4 recognizes a variety of ligands, which are released in response to myocardial ischemia/reperfusion, resulting in the activation of TLR4 inflammatory signaling pathway in the heart, as a mechanism to increase the expression and nuclear translocation of nuclear factor kappa-B (NF-kappa-B) transcription factor [5], which leads to the expression of pro-inflammatory cytokines, including TNF-α, interleukin-1β and interleukin-6, chemokines, the recruitment of lymphocytes, increasing the expression of inducible nitric oxide synthase and matrix degrading enzymes [6], and leading to the acute-inflammatory phase and a source of cardiac cell necrosis. While inflammation is a necessary element during the early stage of remodeling, a prolonged inflammatory response may impair cardiac physiology by promoting left ventricle dilation and excessive scar formation [7]. Hence, timely control of the inflammatory response is crucial to prevent the severity of HF.

Several groups have developed different strategies in mice to study the contribution of TLR4 activation in the cardiac function in response to cardiac ischemia/reperfusion (IR) [8–10], and while all the studies agree on the effect on cardiac necrosis, a disparity of results arise when studying the effect of TLR4 on cardiac function.

Small non-coding RNAs, including RNA aptamers, have been tested in experimental diagnostic and therapeutic diseases [11], including myocardial infarction [12]. ApTOLL is a new therapeutic tool designed to antagonize TLR4. ApTOLL aptamer is a single-stranded oligonucleotide that recognizes and specifically binds to TLR4 by structural interaction, as described [13]. Once folded under physiological conditions, aptamers acquire unique three-dimensional structures based on their nucleotide sequence, conferring target affinity and specificity [14–16]. The protective effect of ApTOLL was recently reported against experimental strokes, a setting in which TLR4 played a crucial role in the initiation of ischemic injury [13].

The present study aimed to evaluate the potential therapeutic effect of ApTOLL as a cardioprotective compound in a porcine model of cardiac IR.

2. Materials and Methods

2.1. Reagents and Equipment

Hematoxylin-eosin (H/E), Trichrome Masson staining reagents, TTC, Evans blue, and fetal bovine serum were from Sigma (Madrid, Spain). Horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibody and liquid 3,3′-diaminobenzidine (DAB) substrate were from Dako (Santa Clara, CA, USA). The anti-Matrix Metalloprotease 9 (MMP-9) antibody and Human Cardiac Troponin 1 Simple-Step ELISA Kit (ab200016) and the Tunel assay kit (ab206386) were from Abcam (Cambridge, UK); the proteome Profiler Array (ARY005B) was from R&D Systems (Minneapolis, MN, USA); the ketamine was from Pfizer (New York, NY, USA); the isoflurane was from Abbvie (North Chicago, IL, USA); the propofol was from Fresenius (Bad Homburg, Germany); the fentanyl was from Kern Pharma (Madrid, Spain); the diazepam was from Roche (Basel, Switzerland); and the amiodarone was from Sanofi Aventis (Gentilly, France).

The following is a list of the most common equipment used for this investigation: The 5415R Refrigerated Centrifuge was from Eppendorf (Hamburg, Germany). The chemiluminescence imaging system Fusion Solo-S and the image analysis software Fusion-Capt were from Vilber-Lourmat (Eberhardzell, Germany). The TCS-SP5 Confocal Microscope was from Leica (Wetzlar, Germany). The microplate reader was from Biotek (Winooski, VT, USA). The NanoDrop One Spectrophotometer
was from Thermo Scientific (Waltham, MA, USA). Guiding catheters, angioplasty balloons, and catheter introducers were from Cordis (Miami, FL, USA). Diagnostic and steerable guidewires were from Boston Scientifics (Malborough, MA, USA). The balloon inflation devices and midazolam were from B.Braun (Melsungen, Germany).

2.2. Animal Model of Coronary Ischemia/Reperfusion

Animal procedures were performed in the Experimental Surgery Department of the Hospital Universitario La Paz (Madrid, Spain), as described [17,18]. The investigation conformed to the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985) and the Animal Welfare Ethics Committee and complied with the EU Directive on experimental animals (63/2010 EU) and related Spanish legislation (RD 53/2013). PROEX 365-15.

Before experimentation, animals were housed for one week to avoid cardiovascular responses derived from anxiety associated with the new environment. Prior to experimentation, the animals underwent a cardiac ultrasound to check for abnormalities of cardiac anatomy and function (Figure S1). Yorkshire female pigs (37.8 ± 5.2 kg) were pre-medicated with intramuscular ketamine 10 mg/kg (Pfizer) and midazolam 0.5 mg/kg (B.Braun). Anesthesia was induced by inhaled isoflurane (Abbvie) and maintained with continuous infusion of propofol 2mL/kg/h (Fresenius), fentanyl 50 µg/kg/h (Kern Pharma), and diazepam 10 µg/kg/h (Roche). Animals were intubated and ventilated with 100% oxygen saturation. The animals received 5000 IU of heparin and amiodarone 2 mg/kg/h (Sanofi Aventis) to avoid blood clotting of catheters and malignant cardiac arrhythmias, respectively. Before balloon inflation, coronary anatomy was visualized to check for vasculature abnormalities.

Ischemia/reperfusion was induced by LAD occlusion for 45 min, using a JL 3 6F catheter and an angioplasty balloon (inflated to the pressure of eight atmospheres). In cases when ventricular fibrillation/ventricular tachycardia occurred, we administered a biphasic DC shock (10–20 joules), combined with direct manual chest compressions. After 45 min of LAD occlusion, the artery was unblocked, and after 10 min of reperfusion, APTOLL was administered intravenously in slow bolus at a dose of 0.078 mg/kg (equivalent dosage previously tested in mice [13]) and diluted in distilled water. The animals were then randomized to a control group (n = 10) or treated with APTOLL (n = 10). A total of 10 mL of arterial blood was obtained from the femoral artery at the following times: before AMI, 50 min, 75 min, 2 h, 8 h, 24 h, 3 days, and 7 days post-AMI. Immediately after collection, plasma was isolated by centrifugation at 3000 rpm for 10 min and all the samples were kept at −80 °C before experimentation and stored for future investigation. Overall, 20% of pigs that were treated with a placebo and 10% that were treated with APTOLL died by day 1 after treatment.

2.3. Echocardiography

Pig hearts were visualized by echocardiography by using a Vivid Q ultrasound system from GE healthcare (General Electric, Chicago, IL, USA), equipped with a 1.9-4 MHz scan head. In anesthetized animals, parasternal short-axis-view images of the heart were recorded in a B-mode to allow M-mode recordings by positioning the cursor in the parasternal short-axis view perpendicular to the interventricular septum and posterior wall of the left ventricle. From these recordings, the following parameters were determined using the on-site software cardiac package: systolic and diastolic interventricular septum thickness (IVS), systolic and diastolic left-ventricle internal diameter (LVID), systolic and diastolic left-ventricle posterior wall thickness (LVPW), left-ventricle ejection fraction (EF), left ventricle shortening fraction (FS), heart rate (HR), and cardiac output (CO). In addition, left ventricle ejection fraction (LVEF) was also measured by using the B-mode Simpson biplane method, using 4 chamber and a 2 chamber left ventricle long axis views, with similar results. To avoid inter-observer derived biases, data acquisition and analysis was performed by one single operator.
2.4. Evans Blue/TTC Staining

The extension of myocardial infarction was evaluated by Evans blue perfusion and TTC staining. By day 7, a catheter inflated at the same position, as in day 0, to avoid Evans blue perfusion downstream to the area at risk, and a pigtail catheter was inserted from the femoral artery and placed up to the left ventricle for Evans blue perfusion into the systemic circulation. After 1 min of perfusion, the animals were sacrificed by injection of a potassium chloride solution, and the hearts were then isolated, washed three times with saline buffer, frozen for 12 h at –20 °C, and chopped into 0.5 cm slices from base to apex. The slices were incubated with 1% TTC dye, dissolved in a saline buffer for 20 min at 37 °C, and then washed for 20 min with 10% paraformaldehyde. Images were acquired with the ImageJ software, discriminating between healthy areas (blue) from the area at risk (dark red) and the pale necrotic area (white), calculating the area of necrosis as percentage respect to the area at risk.

2.5. Confocal Microscopy

Paraffin embedded 0.5 µm heart sections were incubated with anti-MMP-9 (diluted 1:500 in PBS 1.5% BSA) primary antibody overnight at 4 °C. After washing three times with PBS, the slides were incubated with Alexa-Fluor-647 conjugated secondary antibody for 1 h at room temperature. Slides were washed three times with PBS and mounted in PBS media, containing Hoechst for nuclei visualization. Images were taken using a Leica TCS SP5 confocal microscope. At least three different fields per condition were obtained.

2.6. Determination of Cardiac Troponin I

Plasma Troponin I was determined with the commercial Human Cardiac Troponin 1 SimpleStep ELISA Kit (Abcam), following the manufacturer’s instructions.

2.7. Histology and Immunohistochemistry

Histological, immunohistochemical, and immunohistofluorescence procedures were performed, as previously described [19,20].

2.8. Statistical Analysis

All values were given as mean ± S.D. Significance was reported at the 5% level. Whenever comparisons were made with a common control, significance of differences was tested by Dunnett’s modification of the t-test.

3. Results

3.1. ApTOLL Induces Cardiac Protection in Response to IR

To test the effect of ApTOLL, we first determined cardiac troponin-I levels, indicative of ischemic injury [21] at the times indicated, detecting a significant reduction 24 h after IR in pigs treated with 0.078 mg/kg ApTOLL vs. Placebo (Figure 1A). Cardiac ultrasound also revealed a significant reduction of the left ventricle ejection fraction (LVEF) by day 7 in the same pigs (Figure 1B). The rest of the parameters examined did not show differences, with the exception of the shortening fraction (FS), which was reduced by day 7 after treatment with ApTOLL (Figure 2, Table 1).
Figure 1. (A) Cardiac Troponin I (cTnI) levels in plasma collected from pigs treated with 0.078 mg/kg ApTOLL or Placebo at 8 and 24 h after ischemia/reperfusion (IR) (N = 10/group, mean ± SD * p < 0.002 ApTOLL). (B) Left ventricle ejection fraction levels detected by cardiac ultrasound at the times indicated. Representative M-Mode images from Placebo and ApTOLL treated animals, in which end diastolic and systolic thickness of the interventricular septum thickness (IVS) and left-ventricle posterior wall thickness (LVPW) are represented (N = 10/group (d0), N = 9 ApTOLL/8 Placebo (d3, and d7). Mean ± SD * p < 0.001 ApTOLL vs. Placebo).

Figure 2. Echocardiographic parameters collected by day 3 (A) and day 7 (B), respectively, after IR. (N = 9 ApTOLL/8 Placebo. Mean ± SD. EF: * p < 0.0006 ApTOLL vs. Placebo. FS: * p < 0.003 ApTOLL vs. Placebo).
Table 1. Echocardiographic parameters tested by day 3 (D3) and day 7 (D7) after procedure. End diastolic Interventricular septum thickness (IVSD); end diastolic left ventricle internal diameter (LVIDD); end diastolic left ventricular posterior wall thickness (LVPWD); end systolic interventricular septum thickness (IVSS); end systolic left ventricular internal diameter (LVIDS); end systolic left ventricular posterior wall thickness (LVPWS); left ventricle ejection fraction (LVEF); fractional shortening (FS); heart rate (HR); cardiac output (CO). * EF: \( p < 0.001 \) ApTOLL vs. Placebo. FS: \( p < 0.003 \) ApTOLL vs. Placebo.

| PARAMETER            | PLACEBO D3 | APTOLL D3 | PLACEBO D7 | APTOLL D7 | PARAMETER            | PLACEBO D3 | APTOLL D3 | PLACEBO D7 | APTOLL D7 |
|----------------------|------------|-----------|------------|-----------|----------------------|------------|-----------|------------|-----------|
| IVSD (mm)            | 11.68 ± 0.806 | 10.857 ± 0.61 | 10.124 ± 1.357 | 11.353 ± 1.276 | IVSD (mm)            | 15.77 ± 2.264 | 13.562 ± 0.932 | 13.153 ± 2.806 | 14.177 ± 1.678 |
| LVIDD (mm)           | 37.96 ± 4.219 | 39.511 ± 4.319 | 38.488 ± 8.667 | 38.067 ± 6.052 | LVIDD (mm)           | 13.430 ± 2.394 | 9.954 ± 1.746 | 10.475 ± 0.67 | 11.093 ± 2.796 |
| LVPWD (mm)           | 15.77 ± 2.264 | 13.562 ± 0.932 | 13.153 ± 2.806 | 14.177 ± 1.678 | LVPWD (mm)           | 26.28 ± 4.36 | 29.126 ± 3.493 | 27.316 ± 5.860 | 24.705 ± 4.129 |
| IVSS (mm)            | 11.68 ± 0.806 | 10.857 ± 0.61 | 10.124 ± 1.357 | 11.353 ± 1.276 | IVSS (mm)            | 11.024 ± 1.339 | 10.926 ± 1.704 | 11.90 ± 1.722 | 11.353 ± 1.276 |
| LVIDS (mm)           | 26.28 ± 4.36 | 29.126 ± 3.493 | 27.316 ± 5.860 | 24.705 ± 4.129 | LVIDS (mm)           | 15.77 ± 3.383 | 11.024 ± 1.339 | 10.926 ± 1.704 | 11.90 ± 1.722 |
| LVPWS (mm)           | 49.07 ± 5.91 | 46.31 ± 2.60 | 55.14 ± 4.947 | 66.85 ± 3.196 * | EF (%)               | 21.25 ± 3.77 | 20.272 ± 1.443 | 28.55 ± 2.530 | 34.75 ± 2.492 * |
| CO (mL/sec)          | 3614 ± 2068.651 | 3940.33 ± 1217.115 | 3801.111 ± 1.826 | 3918.875 ± 1356 | HR (bpm)             | 99 ± 31.494 | 111.101 ± 27.31 | 103.444 ± 31.269 | 91.875 ± 11.849 |
| FS (%)               | 49.07 ± 5.91 | 46.31 ± 2.60 | 55.14 ± 4.947 | 66.85 ± 3.196 * | FS (%)               | 55.14 ± 4.947 | 66.85 ± 3.196 | 28.55 ± 2.530 | 34.75 ± 2.492 * |
| HR (bpm)             | 26.28 ± 4.36 | 29.126 ± 3.493 | 27.316 ± 5.860 | 24.705 ± 4.129 | LVPWS                | 11.68 ± .806 | 10.857 ± 0.61 | 10.124 ± 1.357 | 11.353 ± 1.276 |
| EF (%)               | 49.07 ± 5.91 | 46.31 ± 2.60 | 55.14 ± 4.947 | 66.85 ± 3.196 * | EF (%)               | 55.14 ± 4.947 | 66.85 ± 3.196 | 28.55 ± 2.530 | 34.75 ± 2.492 * |
| LVIDD (mm)           | 37.96 ± 4.219 | 39.511 ± 4.319 | 38.488 ± 8.667 | 38.067 ± 6.052 | LVIDD (mm)           | 13.430 ± 2.394 | 9.954 ± 1.746 | 10.475 ± 0.67 | 11.093 ± 2.796 |
| LVPWD (mm)           | 15.77 ± 2.264 | 13.562 ± 0.932 | 13.153 ± 2.806 | 14.177 ± 1.678 | LVPWD (mm)           | 26.28 ± 4.36 | 29.126 ± 3.493 | 27.316 ± 5.860 | 24.705 ± 4.129 |
| IVSS (mm)            | 11.68 ± 0.806 | 10.857 ± 0.61 | 10.124 ± 1.357 | 11.353 ± 1.276 | IVSS (mm)            | 15.77 ± 3.383 | 11.024 ± 1.339 | 10.926 ± 1.704 | 11.90 ± 1.722 |
| LVIDS (mm)           | 26.28 ± 4.36 | 29.126 ± 3.493 | 27.316 ± 5.860 | 24.705 ± 4.129 | LVIDS (mm)           | 15.77 ± 3.383 | 11.024 ± 1.339 | 10.926 ± 1.704 | 11.90 ± 1.722 |
| LVPWS (mm)           | 49.07 ± 5.91 | 46.31 ± 2.60 | 55.14 ± 4.947 | 66.85 ± 3.196 * | EF (%)               | 21.25 ± 3.77 | 20.272 ± 1.443 | 28.55 ± 2.530 | 34.75 ± 2.492 * |
| CO (mL/sec)          | 3614 ± 2068.651 | 3940.33 ± 1217.115 | 3801.111 ± 1.826 | 3918.875 ± 1356 | HR (bpm)             | 99 ± 31.494 | 111.101 ± 27.31 | 103.444 ± 31.269 | 91.875 ± 11.849 |
| FS (%)               | 49.07 ± 5.91 | 46.31 ± 2.60 | 55.14 ± 4.947 | 66.85 ± 3.196 * | FS (%)               | 55.14 ± 4.947 | 66.85 ± 3.196 | 28.55 ± 2.530 | 34.75 ± 2.492 * |

3.2. ApTOLL Reduces Left Ventricle Necrosis and Fibrosis by Day 7 after IR

We next asked whether ApTOLL-induced improvement of cardiac function was due to preventing cardiac necrosis. Evans blue/TTC double staining (see methods for details) showed that after 7 days of treatment, the necrotic area was significantly reduced in the hearts of pigs treated with ApTOLL (Figure 3A). In the same way, H/E, Masson Trichrome, and Tunel staining of ventricular sections showed reduced fibrosis, necrosis, and apoptosis in response to ApTOLL (Figure 3B), suggesting the antagonizing of TLR4, leading to inhibition of the downstream necrotic molecular cascade.

![Figure 3](image-url)

**Figure 3.** (A) Evans blue/TTC double staining performed in 0.5 cm heart sections isolated 7 days after IR from pigs treated with 0.078 mg/kg ApTOLL of Placebo (N = 9 ApTOLL/8 Placebo. Mean ± SD. * \( p < 0.002 \) Placebo (Vehicle) vs. ApTOLL). (B) Left panels: H/E staining of heart sections from healthy and necrotic areas of hearts collected from pigs treated with 0.078 mg/kg ApTOLL or Placebo. Middle Right panel: Masson Trichrome staining of necrotic sections. Right panel. Tunel assay staining of necrotic sections. N = 5 ApTOLL/4 Placebo.
3.3. APTOLL Inhibits the Expression of MMP-9 by Day 7 after IR

Degradation of the extracellular matrix is a critical step during myocardial remodeling and repair. Matrix Metalloprotease 9 (MMP-9), a marker of adverse remodeling [22], plays a key role in this process as it degrades the extracellular matrix components. In pigs treated with ApTOLL, the expression of MMP-9 by day 7 after IR was significantly reduced by 40%, compared to the Placebo group, as detected in the same heart sections as before by confocal microscopy immunofluorescence, with specific anti-MMP-9 antibodies. In the same way, MMP-9 activity assay also revealed a significant reduction in response to ApTOLL by day 7 after treatment (Figure 4).

![Confocal microscopy detection of Matrix Metalloprotease 9 (MMP-9; red) in heart sections of pigs treated with 0.078 mg/kg ApTOLL or Placebo, 7 days after IR. Nuclei were stained with DAPI (N = 5 ApTOLL/4 Placebo. Mean ± SD. *p < 0.001 Placebo vs. ApTOLL). Lower graph. MMP-9 activity assay in the same hearts (N = 3/condition. Mean ± SD. *p < 0.004 Necrotic Placebo vs. Necrotic ApTOLL).](image)

Figure 4. Confocal microscopy detection of Matrix Metalloprotease 9 (MMP-9; red) in heart sections of pigs treated with 0.078 mg/kg ApTOLL or Placebo, 7 days after IR. Nuclei were stained with DAPI (N = 5 ApTOLL/4 Placebo. Mean ± SD. *p < 0.001 Placebo vs. ApTOLL). Lower graph. MMP-9 activity assay in the same hearts (N = 3/condition. Mean ± SD. *p < 0.004 Necrotic Placebo vs. Necrotic ApTOLL).

3.4. ApTOLL Reduces the Expression of Pro-Inflammatory Cytokines 7 Days After Reperfusion

To test the effect of antagonizing TLR4, the level of 36 cytokines and chemokines was assessed in plasma collected 7 days after IR. We evaluated the levels of CCL1, CCL2, MIP1-A-B, CCL5, CD40L, C5/C5A, CXCL1, CXCL10, CXCL11, CXCL12, G-CSF, GM-CSF, ICAM-1, INFγ, IL1-A, IL1-B, IL-1RA, IL2, IL4, IL5, IL6, IL8, IL10, IL12, IL13, IL16, IL17-A, IL17- E, IL18, IL21, IL27, IL32, MIF, SERPIN-E1, TNF-A, and TREM-1, detecting significant differences in 24 cytokines (Table 2).
Table 2. Plasma levels of cytokines differentially expressed 7 days after procedure.

| CYTOKINE   | PLACEBO   | APTOLL    |
|------------|-----------|-----------|
| CCL5       | 1.108 ± 0.141 | 0.27 ± 0.070 |
| CXCL1      | 0.429 ± 0.024 | 0.105 ± 0.023 |
| CXCL10     | 1.542 ± 0.237 | 0.37 ± 0.07 |
| G-CSF      | 0.372 ± 0.088 | 0.0732 ± 0.014 |
| GM-CSF     | 0.261 ± 0.057 | 0.031 ± 0.009 |
| ICAM-1     | 0.154 ± 0.030 | 0.045 ± 0.009 |
| INF-γ      | 0.092 ± 0.019 | 0     |
| IL1-α      | 0.255 ± 0.043 | 0.108 ± 0.018 |
| IL1-β      | 0.616 ± 0.146 | 0.047 ± 0.146 |
| IL-1RA     | 0.193 ± 0.023 | 0.421 ± 0.123 |
| IL-2       | 0.493 ± 0.074 | 0.141 ± 0.036 |
| IL5        | 0.197 ± 0.020 | 0.014 ± 0.004 |
| IL-6       | 0.309 ± 0.040 | 0.165 ± 0.043 |
| IL-8       | 0.317 ± 0.042 | 0.183 ± 0.047 |
| IL-12      | 0.392 ± 0.054 | 0.213 ± 0.054 |
| IL-16      | 0.306 ± 0.031 | 0.16 ± 0.046 |
| IL-17A     | 0.42 ± 0.042  | 0.109 ± 0.032 |
| IL-18      | 0.311 ± 0.077 | 0.504 ± 0.116 |
| IL-21      | 0.466 ± 0.074 | 0.159 ± 0.029 |
| IL-27      | 0.348 ± 0.037 | 0     |
| MIF        | 1.359 ± 0.200 | 0.527 ± 0.089 |
| SERPIN-E1  | 0.876 ± 0.095 | 0.454 ± 0.076 |
| TNF-α      | 0.52 ± 0.040  | 0.152 ± 0.045 |
| TREM-1     | 0.4192 ± 0.039 | 0.105 ± 0.031 |

In particular, ApTOLL induced chemokine downregulation of CCL5, CXCL1, G-CSF, CXCL10 (Figure 5A), and pro-inflammatory cytokines, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL5, IL-6, IL-8, IL-12, IL-16, IL-17A, IL-18, and TNFα. It is important to highlight IL-1, IL-6, IL-8, and TNF-α for their key roles in the inflammatory response during an AMI. However, the levels of IL-18 were upregulated in response to ApTOLL (Figure 5B). ApTOLL also upregulated the levels of IL-1RA (Figure 5C or D), an anti-inflammatory cytokine, but downregulated the levels of resolving cytokines IL-21, MIF, SERPIN-E1, and TREM-1 (Figure 5C, together with CD40, ICAM-1, and IL-27 (Figure 5D).
Figure 5. Plasma levels of selected cytokines detected by day 7 after IR. (A) Chemokines; (B) pro-inflammatory cytokines; (C) resolving cytokines; (D) miscellaneous. All cytokines depicted presented statistically significant differences between ApTOLL vs. PLACEBO, with p values < 0.001.(N = 9 ApTOLL/8 PLACEBO. Mean ± SD).

4. Discussion

In the current work, we show that ApTOLL may represent a novel therapeutic target for the treatment of AMI. In pigs subjected to IR, the levels of cardiac troponins [23] were reduced 24 h after administration of ApTOLL, showing a significant improvement of cardiac function by day 7, as a result of left ventricle prevention of necrosis, including preservation of the extracellular matrix, as shown by the reduction of MMP-9 expression. Our results point towards the reduction of the expression of pro-inflammatory cytokines as a mechanism, at least in part, responsible for cardiac protection induced by ApTOLL.

Others have shown that TLR4 correlates with a bad outcome in AMI [24,25]. Several reports show a close correlation between TLR4 and the downstream proinflammatory NF-kappa B transcription factor and ways of inhibition to reduce several inflammatory conditions [9]. However, most results have been gathered in vitro and in murine models of AMI [26], while this is the first report in which, by using a brand-new compound against TLR4, a significant response is achieved in a porcine model of AMI.

Other studies have demonstrated that TLR4 gene silencing reduces the levels of MMP-9 in human aortic smooth muscle cells in the context of atherosclerosis [27]. Our data show that ApTOLL also...
prevents extracellular matrix degradation, at least by reducing the expression of MMP-9 by day 7 after IR, indicative of cardiovascular injury.

The role of TLR4 in activating the immune response have been thoroughly explored in recent years. TLR4 promotes nuclear NF-kB translocation both in MyD88 dependent and independent pathways and consequently results in the activation of inflammatory pathways and cytokine release [28]. Thus, we evaluated the release of inflammatory-related cytokines at 7 days post-reperfusion, a time point in which the anti-inflammatory-resolution phase is about to start, and, still, TLR4 induced inflammation that was consistently significant [29–32]. As shown here, ApTOLL significantly reduced the levels of the proinflammatory cytokines implicated in the progression of AMI.

TLR4 increases the levels of IL-1β, IL-6, IL-8, and TNF-α, contributing to inducing cardiac damage in AMI [31,32], while ApTOLL did the opposite, as evidenced in this work. Therefore, ApTOLL may help to maintain heart contractility by preventing cardiac cell death during acute myocardial infarction. In the same way, chemokines that are overexpressed in response to TLR4 and NF-κB [33] were also inhibited, hence improving heart function by preventing the recruitment and migration of immune cells.

Resolving cytokines neutralize and regulate latter stages of the inflammatory response [34]. Two important resolving cytokines, such as IL-4 and IL10, were not affected by ApTOLL, while others in apparent contradiction were downregulated. To fully understand the contribution of ApTOLL in the resolution of inflammation, further investigations should focus on the effect of ApTOLL at later time points to evaluate the contribution of neutrophil and macrophage polarization to a resolving stage [35]. Interestingly, the levels of interleukin 1 receptor antagonist (IL-1RA) were upregulated after treatment with ApTOLL, a cardioprotective molecule that binds to the receptor of IL-1, blocking its activity [36].

The effect of ApTOLL on IL-18 also constitutes a potentially contradictory, since IL-18 is known to induce a pro-inflammatory environment under several circumstances. However, reports showing the pro- and anti-inflammatory properties of IL-18 have emerged, since IL18 binds to IL-18 binding protein (IL-18BP), which mediates IL-37-induced anti-inflammatory effects [37]. Thereby, and besides limitations, including sample size and species of the study, ApTOLL = induced IL18 expression in AMI requires additional investigation.

We used a pig model of coronary ischemia/reperfusion rather than using rodent models, which allows the use of a significant number of individuals at a low economic cost, because the rodent cardiovascular system differs substantially from humans. However, although the procedure used in this work resembles the series of events of patients after reperfusion in the cathlab, the cost of experimentation in these circumstances is rather high when compared to mice, which in the end becomes a strong limitation of the study. Hence, further investigation is required to fully validate our results in patients, as other molecular markers have been tested [38], and to evaluate the relevance of using ApTOLL to prevent the development of the deadly inflammatory response in high-risk populations, as well as to investigate a long-term effect of ApTOLL in heart failure, which represents a significant economic burden given the high number of patients worldwide.

5. Conclusions

Blocking the inflammatory response has emerged as one of the main targets to prevent harmful outcomes after AMI. ApTOLL is a promising new tool to achieve this objective, blocking TLR4, one of the upstream molecules that trigger the inflammatory response. Preventing the release of inflammatory cytokines, it is possible to avoid myocardial damage by reducing cardiac fibrosis through prevention of extracellular matrix degradation and, hence, preserving the ventricular function. Further experiments must be performed, but our results make ApTOLL a potential tool for future clinical studies in the onset of AMI.

6. Patents

International Application of: APTATARGETS. S.L.
International Application Number: PCT/IB2020/054655
International Filling Date: May 16, 2020
Title: TREATMENT OF TLR-4 MEDIATED DISEASES AND CONDITIONS WITH APTAMERS TARGETING TL4-4.

Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/8/1167/s1, Figure S1: Basal cardiac ultrasound parameters of selected pigs included in the study.

Author Contributions: Conceptualization, D.P., M.H.-J., and C.Z.; methodology, R.R.-C., I.H., L.T., and C.Z.; validation, C.Z.; formal analysis, C.Z. and J.L.Z.; investigation, R.R.-C., I.H., J.D.-M., L.T. and C.Z.; writing—original draft preparation, C.Z.; writing—review and editing, R.R.-C., I.H., L.T., and J.L.Z; supervision, C.Z.; funding acquisition, C.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by “Centro para el Desarrollo Técnico Industrial CDTI”, grant number EXP 0014980/SNEO–20171153”, to Aptatargets SL.

Acknowledgments: We thank Mª Eugenia Zarabozo and David Segarra for their input in the development of the project.

Conflicts of Interest: D.P. and M.H.-J., are employees of Aptatargets SL. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Benjamin, E.J.; Muntner, P.; Alonso, A.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Das, S.R.; et al. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. Circulation 2019, 139. [CrossRef]
2. Prabhu, S.D.; Frangogiannis, N.G. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circ. Res. 2016, 119, 91–112. [CrossRef]
3. Nahrendorf, M.; Pittet, M.J.; Swirski, F.K. Monocytes: Protagonists of Infarct Inflammation and Repair After Myocardial Infarction. Circulation 2010, 121, 2437–2445. [CrossRef]
4. Frangogiannis, N.G. Regulation of the Inflammatory Response in Cardiac Repair. Circ Res 2012, 110, 159–173. [CrossRef]
5. Bhattacharya, D.; Yusuf, N. Expression of Toll-Like Receptors on Breast Tumors: Taking a Toll on Tumor Microenvironment. Int. J. Breast Cancer 2012, 2012, 1–6. [CrossRef] [PubMed]
6. Sun, N.; Wang, H.; Wang, L. Protective effects of ghrelin against oxidative stress, inducible nitric oxide synthase and inflammation in a mouse model of myocardial ischemia/reperfusion injury via the HMGB1 and TLR4/NF-κB pathway. Mol. Med. Rep. 2016, 14, 2764–2770. [CrossRef] [PubMed]
7. Frangogiannis, N.G. Targeting the inflammatory response in healing myocardial infarcts. Curr. Med. Chem. 2006, 13, 1877–1893. [CrossRef] [PubMed]
8. Avlas, O.; Srara, S.; Shainberg, A.; Aravot, D.; Hochhauser, E. Silencing cardiomyocyte TLR4 reduces injury following hypoxia. Exp. Cell Res. 2016, 348, 115–122. [CrossRef] [PubMed]
9. Fujiwara, M.; Matoba, T.; Koga, J.-I.; Okahara, A.; Funamoto, D.; Nakano, K.; Tsutsui, H.; Egashira, K. Nanoparticle incorporating Toll-like receptor 4 inhibitor attenuates myocardial ischemia–reperfusion injury by inhibiting monocyte-mediated inflammation in mice. Cardiovasc. Res. 2019, 115, 1244–1255. [CrossRef] [PubMed]
10. Ogawa, K.; Hirooka, Y.; Kishi, T.; Ide, T.; Sunagawa, K. Partially Silencing Brain Toll-Like Receptor 4 Prevents in Part Left Ventricular Remodeling with Sympathoinhibition in Rats with Myocardial Infarction-Induced Heart Failure. PLoS ONE 2013, 8, e69053. [CrossRef]
11. Leonard, M.; Zhang, D.; Zhang, X. Small Non-Coding RNAs and Aptamers in Diagnostics and Therapeutics. Adv. Struct. Saf. Stud. 2015, 1296, 225–233. [CrossRef]
12. Jung, M.; Dodsworth, M.; Thum, T. Inflammatory cells and their non-coding RNAs as targets for treating myocardial infarction. Basic Res. Cardiol. 2018, 114, 4. [CrossRef]
13. Fernández, G.; Moraga, A.; Cuartero, M.; García-Culebras, A.; Peña-Martínez, C.; Pradillo, J.M.; Hernández-Jiménez, M.; Sacristán, S.; Ayuso, M.I.; Gonzalo-Gobernado, R.; et al. TLR4-Binding DNA Aptamers Show a Protective Effect against Acute Stroke in Animal Models. Mol. Ther. 2018, 26, 2047–2059. [CrossRef] [PubMed]
14. Ramos, E.; Piñéiro, D.; Soto, M.; Abanades, D.R.; Martin, M.E.; Salinas, M.; Gonzalez, V.M.; Alvarez, M.S. A DNA aptamer population specifically detects Leishmania infantum H2A antigen. *Lab. Investig.* **2007**, *87*, 409–416. [CrossRef] [PubMed]

15. White, R.R.; Sullivan, B.A.; Rusconi, C.P. Developing aptamers into therapeutics. *J. Clin. Invest.* **2000**, *106*, 929–934. [CrossRef] [PubMed]

16. Bouchard, P.; Hutabarat, R.; Thompson, K. Discovery and Development of Therapeutic Aptamers. *Annu. Rev. Pharmacol. Toxicol.* **2010**, *50*, 237–257. [CrossRef] [PubMed]

17. Rossello, X.; Rodríguez-Sinovas, A.; Vilahur, G.; Crisóstomo, V.; Jorge, I.; Zaragoza, C.; Zamorano, J.L.; Bermejo, J.; Ordoñez, A.; Boscá, L.; et al. CIBER-CLAP (CIBERCV Cardioprotection Large Animal Platform): A multicenter preclinical network for testing reproducibility in cardiovascular interventions. *Sci. Rep.* **2019**, *9*, 1–11. [CrossRef]

18. Betker, H.E.; Hausenloy, D.; Andreadou, I.; Antonucci, S.; Boengler, K.; Davidson, S.M.; Deshwal, S.; Devaux, Y.; Di Lisa, F.; Di Sante, M.; et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. *Basic Res. Cardiol.* **2018**, *113*, 39. [CrossRef]

19. Tarin, C.; Lavin, B.; Gomez, M.; Saura, M.; Diez-Juan, A.; Zaragoza, C. The extracellular matrix metalloproteinase inducer EMMPRIN is a target of nitric oxide in myocardial ischemia/reperfusion. *Free. Radic. Biol. Med.* **2011**, *51*, 387–395. [CrossRef]

20. Cuadrado, I.; Castejon, B.; Martin, A.M.; Saura, M.; Reventí, P.; Zamorano, J.L.; Zaragoza, C. Nitric Oxide Induces Cardiac Protection by Preventing Extracellular Matrix Degradation through the Complex Caveolin-3/EMMPRIN in Cardiac Myocytes. *PLoS ONE* **2016**, *11*, e0162912. [CrossRef]

21. Sadony, V.; Körber, M.; Albes, G.; Podtschaske, V.; Egegen, T.; Tröskén, T.; Ravens, U.; Scheulen, M.E. Cardiac troponin I plasma levels for diagnosis and quantitation of perioperative myocardial damage in patients undergoing coronary artery bypass surgery. *Eur. J. Cardio-Thoracic Surg.* **1998**, *13*, 57–65. [CrossRef]

22. Phatharajaree, W.; Phrommintikul, A.; Chattipakorn, N. Matrix metalloproteinases and myocardial infarction. *Can. J. Cardiol.* **2007**, *23*, 727–733. [CrossRef]

23. Jeremias, A. The utility of troponin measurement to detect myocardial infarction: Review of the current findings. *Vasc. Heal. Risk Manag.* **2010**, *6*, 691. [CrossRef] [PubMed]

24. Satoh, M.; Shimoda, Y.; Maesawa, C.; Akatsu, T.; Ishikawa, Y.; Minami, Y.; Hiramori, K.; Nakamura, M. Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. *Int. J. Cardiol.* **2006**, *109*, 226–234. [CrossRef]

25. Ma, H.; Du, J.; Feng, X.; Zhang, Y.; Wang, H.; Ding, S.; Huang, A.; Ma, J. Rosiglitazone alleviates myocardial apoptosis in rats with acute myocardial infarction via inhibiting TLR4/NF-κB signaling pathway. *Exp. Ther. Med.* **2020**, *19*, 2491–2496. [CrossRef]

26. Oyama, J.-I.; Blais, C., Jr.; Liu, X.; Pu, M.; Kobzik, L.; Kelly, R.A.; Bourcier, T. Reduced Myocardial Ischemia-Reperfusion Injury in Toll-Like Receptor 4-Deficient Mice. *Circulation* **2004**, *109*, 784–789. [CrossRef]

27. Li, H.; Xu, H.; Liu, S. Toll-like receptors 4 induces expression of matrix metalloproteinase-9 in human aortic smooth muscle cells. *Mol. Biol. Rep.* **2010**, *38*, 1419–1423. [CrossRef]

28. Mann, D.L. The emerging role of innate immunity in the heart and vascular system: For whom the cell toils. *Circ. Res.* **2011**, *108*, 1133–1145. [CrossRef]

29. Ong, S.-B.; Hernández-Reséndiz, S.; Crespo-Avila, G.E.; Mukhametshina, R.T.; Kwek, X.-Y.; Cabrera-Fuentes, H.A.; Hausenloy, D.J. Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. *Pharmacol. Ther.* **2018**, *186*, 73–87. [CrossRef]

30. Tapp, L.D.; Shantsila, E.; Wrigley, B.J.; Montoro-Garcia, S.; Lip, G.Y.H. TLR4 expression on monocyte subsets in myocardial infarction. *J. Intern. Med.* **2012**, *273*, 294–305. [CrossRef]

31. Yokoyama, T.; Komori, A.; Nakamura, M.; Takii, Y.; Kamihira, T.; Shimoda, S.; Mori, T.; Fujiwara, S.; Koyabu, M.; Taniguchi, K.; et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. *Liver Int.* **2006**, *26*, 467–476. [CrossRef] [PubMed]

32. Cha, J.; Wang, Z.; Ao, L.; Zou, N.; Dinarello, C.A.; Banerjee, A.; Fullerton, D.A.; Meng, X. Cytokines Link Toll-Like Receptor 4 Signaling to Cardiac Dysfunction After Global Myocardial Ischemia. *Ann. Thorac. Surg.* **2008**, *85*, 1678–1685. [CrossRef] [PubMed]
33. Montecucco, F.; Braunersreuther, V.; Lenglet, S.; Delattre, B.M.; Pelli, G.; Buatois, V.; Guilhot, F.; Galan, K.; Vuilleumier, N.; Ferlin, W.G.; et al. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. *Eur. Hear. J.* 2011, 33, 1964–1974. [CrossRef] [PubMed]

34. Neri, M.; Fineschi, V.; Paolo, M.; Pomara, C.; Riezzo, I.; Turilliassi, E.; Cerretani, D. Cardiac Oxidative Stress and Inflammatory Cytokines Response after Myocardial Infarction. *Curr. Vasc. Pharmacol.* 2015, 13, 26–36. [CrossRef] [PubMed]

35. García-Culebras, A.; Durán-Laforet, V.; Peña-Martínez, C.; Moraga, A.; Ballesteros, I.; Cuartero, M.I.; De La Parra, J.; Palma-Tortosa, S.; Hidalgo, A.; Corbi, A.L.; et al. Role of TLR4 (Toll-Like Receptor 4) in N1/N2 Neutrophil Programming After Stroke. *Stroke* 2019, 50, 2922–2932. [CrossRef]

36. Zhu, J.; Huang, J.; Dai, D.; Wang, X.; Gao, J.; Han, W.; Zhang, R. Recombinant human interleukin-1 receptor antagonist treatment protects rats from myocardial ischemia–reperfusion injury. *Biomed. Pharmacother.* 2019, 111, 1–5. [CrossRef]

37. Kaplanski, G. Interleukin-18: Biological properties and role in disease pathogenesis. *Immunol. Rev.* 2017, 281, 138–153. [CrossRef]

38. Coverstone, E.D.; Bach, R.G.; Chen, L.; Bierut, L.J.; Li, A.Y.; Lenzini, P.A.; O’Neill, H.C.; Spertus, J.A.; Sucharov, C.C.; Sitzel, J.A.; et al. A novel genetic marker of decreased inflammation and improved survival after acute myocardial infarction. *Basic Res. Cardiol.* 2018, 113, 38. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).